Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted.
Yellowstone Biosciences has raised $20.9M in total funding. The most recent round was Series A. The last funding was announced in June 2024.
Yellowstone Biosciences's investors include Syncona Partners LLP.
Yellowstone Biosciences is headquartered in Oxford, United Kingdom.
Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted.
Yellowstone Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Yellowstone Biosciences — Funding & Investors." VCBacked, June 20, 2024, https://www.vcbacked.co/company/yellowstone-biosciences. Accessed August 14, 2026.
VCBacked. (2024). Yellowstone Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/yellowstone-biosciences
{{cite web |title=Yellowstone Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/yellowstone-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated